AG˹ٷ

STOCK TITAN

[SCHEDULE 13D/A] MetLife, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

MetLife, Inc. � Schedule 13D/A (Amendment No. 102)

The Board of Directors, acting as the sole reporting person, updates its disclosure on common stock held in the MetLife Policyholder Trust formed during the 2000 demutualization. As of 31-Jul-2025 the Trust owns 108,242,821 shares, representing 16.28 % of outstanding stock. The Board possesses shared voting power over all shares but no sole voting or dispositive power; economic rights remain with policyholder beneficiaries.

The position declined by 1,161,259 shares since the 28-Apr-2025 amendment, primarily from beneficiary withdrawals, the Trust’s purchase-and-sale program and routine escheatment. No director paid consideration for the shares and no new acquisitions, sales or strategic actions are announced. Voting mechanics, beneficiary withdrawal rights and other trust provisions remain unchanged. Apart from the routine share reduction, the filing contains no material transactions or changes in corporate control intent.

MetLife, Inc. � Schedule 13D/A (Emendamento n. 102)

Il Consiglio di Amministrazione, in qualità di unico soggetto segnalante, aggiorna la propria comunicazione sulle azioni ordinarie detenute nel MetLife Policyholder Trust costituito durante la demutualizzazione del 2000. Al 31 luglio 2025, il Trust detiene 108.242.821 azioni, pari al 16,28% del capitale sociale in circolazione. Il Consiglio detiene potere di voto condiviso su tutte le azioni ma nessun potere di voto o dispositive esclusivo; i diritti economici restano in capo ai beneficiari assicurati.

La posizione è diminuita di 1.161.259 azioni rispetto all’emendamento del 28 aprile 2025, principalmente a causa di prelievi da parte dei beneficiari, del programma di acquisto e vendita del Trust e della consueta devoluzione. Nessun amministratore ha corrisposto un corrispettivo per le azioni e non sono state annunciate nuove acquisizioni, vendite o azioni strategiche. Le modalità di voto, i diritti di prelievo dei beneficiari e le altre disposizioni del trust rimangono invariate. A parte la riduzione ordinaria delle azioni, il deposito non contiene transazioni rilevanti o cambiamenti nell’intento di controllo societario.

MetLife, Inc. � Schedule 13D/A (Enmienda n.º 102)

La Junta Directiva, actuando como único informante, actualiza su declaración sobre las acciones ordinarias en el MetLife Policyholder Trust formado durante la desmutualización de 2000. A fecha 31 de julio de 2025, el Trust posee 108.242.821 acciones, que representan el 16,28% del capital en circulación. La Junta tiene poder de voto compartido sobre todas las acciones pero sin poder de voto o disposición exclusivo; los derechos económicos permanecen con los beneficiarios asegurados.

La posición disminuyó en 1.161.259 acciones desde la enmienda del 28 de abril de 2025, principalmente por retiros de beneficiarios, el programa de compra y venta del Trust y la escisión rutinaria. Ningún director pagó por las acciones y no se anuncian nuevas adquisiciones, ventas o acciones estratégicas. La mecánica de votación, los derechos de retiro de los beneficiarios y otras disposiciones del trust permanecen sin cambios. Aparte de la reducción rutinaria de acciones, el informe no contiene transacciones materiales ni cambios en la intención de control corporativo.

MetLife, Inc. � Schedule 13D/A (수정� 번호 102)

이사회는 단일 보고자로� 2000� 변상조� 해체 과정에서 설립� MetLife Policyholder Trust가 보유� 보통주에 대� 공시� 업데이트합니�. 2025� 7� 31� 기준으로 신탁은 108,242,821�� 보유하고 있으�, 이는 발행 주식� 16.28%� 해당합니�. 이사회는 모든 주식� 대� 공동 의결�� 보유하지� 단독 의결권이� 처분권은 없습니다; 경제� 권리� 보험 계약� 수혜자에� 귀속됩니다.

� 지분은 2025� 4� 28� 수정� 이후 1,161,259� 감소했으�, 주로 수혜� 인출, 신탁� 매매 프로그램 � 정기 소멸� 따른 것입니다. 이사들은 주식� 대� 대가� 지불하지 않았으며, 새로� 취득, 매각 또는 전략� 조치� 발표되지 않았습니�. 의결 방식, 수혜� 인출 권리 � 기타 신탁 조항은 변경되지 않았습니�. 정기적인 주식 감소 외에� 중요� 거래� 기업 지배권 변� 의도� 없습니다.

MetLife, Inc. � Schedule 13D/A (Amendement n° 102)

Le Conseil d'administration, agissant en tant que seul déclarant, met à jour sa divulgation sur les actions ordinaires détenues dans le MetLife Policyholder Trust créé lors de la démétualisation de 2000. Au 31 juillet 2025, le Trust détient 108 242 821 actions, représentant 16,28 % du capital en circulation. Le Conseil détient un pouvoir de vote partagé sur toutes les actions mais aucun pouvoir de vote ou de disposition exclusif ; les droits économiques restent aux bénéficiaires assurés.

La position a diminué de 1 161 259 actions depuis l'amendement du 28 avril 2025, principalement en raison des retraits des bénéficiaires, du programme d'achat-vente du Trust et des déchéances routinières. Aucun administrateur n'a payé de contrepartie pour les actions et aucune nouvelle acquisition, vente ou action stratégique n'est annoncée. Les modalités de vote, les droits de retrait des bénéficiaires et les autres dispositions du trust restent inchangés. Hormis la réduction routinière des actions, le dépôt ne contient aucune transaction importante ni changement d'intention de contrôle de l'entreprise.

MetLife, Inc. � Schedule 13D/A (Nachtrag Nr. 102)

Der Vorstand, als alleiniger Meldender, aktualisiert seine Angaben zu den Stammaktien, die im MetLife Policyholder Trust gehalten werden, der während der Demutualisierung im Jahr 2000 gegründet wurde. Zum 31. Juli 2025 hält der Trust 108.242.821 Aktien, was 16,28 % des ausstehenden Aktienkapitals entspricht. Der Vorstand besitzt gemeinsames Stimmrecht über alle Aktien, jedoch kein alleiniges Stimm- oder Verfügungsrecht; die wirtschaftlichen Rechte verbleiben bei den versicherten Begünstigten.

Die Position verringerte sich seit der Änderung vom 28. April 2025 um 1.161.259 Aktien, hauptsächlich aufgrund von Auszahlungen an Begünstigte, dem Kauf- und Verkaufsprogramm des Trusts sowie routinemäßiger Verfall. Kein Direktor hat eine Gegenleistung für die Aktien gezahlt, und es werden keine neuen Erwerbe, Verkäufe oder strategischen Maßnahmen angekündigt. Die Abstimmungsmodalitäten, die Auszahlungsrechte der Begünstigten und andere Trust-Bestimmungen bleiben unverändert. Abgesehen von der routinemäßigen Aktienreduktion enthält die Meldung keine wesentlichen Transaktionen oder Änderungen der Absicht zur Unternehmenskontrolle.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine update; Board still controls 16.3 % via trust, share count down slightly, no strategic signal.

The amendment simply refreshes figures for shares in the MetLife Policyholder Trust. With 108.2 M shares, the stake remains sizeable but expectedly declines as policyholders withdraw shares. Because directors have only shared voting rights and lack dispositive control, the trust stake is not an active investment position and does not alter free-float materially. Absent purchases or sales by insiders, the filing is informational and should not affect valuation or liquidity.

TL;DR: Governance mechanics unchanged; trust continues to vote per Board guidance except on beneficiary matters.

The disclosure reconfirms that the Policyholder Trust votes in line with Board recommendations, safeguarding management influence while honoring beneficiary rights on key consent matters. No amendments to trust governance, withdrawal rights or voting algorithms were introduced. Therefore, the company’s control architecture and shareholder rights profile remain stable. Impact on governance risk assessment is neutral.

MetLife, Inc. � Schedule 13D/A (Emendamento n. 102)

Il Consiglio di Amministrazione, in qualità di unico soggetto segnalante, aggiorna la propria comunicazione sulle azioni ordinarie detenute nel MetLife Policyholder Trust costituito durante la demutualizzazione del 2000. Al 31 luglio 2025, il Trust detiene 108.242.821 azioni, pari al 16,28% del capitale sociale in circolazione. Il Consiglio detiene potere di voto condiviso su tutte le azioni ma nessun potere di voto o dispositive esclusivo; i diritti economici restano in capo ai beneficiari assicurati.

La posizione è diminuita di 1.161.259 azioni rispetto all’emendamento del 28 aprile 2025, principalmente a causa di prelievi da parte dei beneficiari, del programma di acquisto e vendita del Trust e della consueta devoluzione. Nessun amministratore ha corrisposto un corrispettivo per le azioni e non sono state annunciate nuove acquisizioni, vendite o azioni strategiche. Le modalità di voto, i diritti di prelievo dei beneficiari e le altre disposizioni del trust rimangono invariate. A parte la riduzione ordinaria delle azioni, il deposito non contiene transazioni rilevanti o cambiamenti nell’intento di controllo societario.

MetLife, Inc. � Schedule 13D/A (Enmienda n.º 102)

La Junta Directiva, actuando como único informante, actualiza su declaración sobre las acciones ordinarias en el MetLife Policyholder Trust formado durante la desmutualización de 2000. A fecha 31 de julio de 2025, el Trust posee 108.242.821 acciones, que representan el 16,28% del capital en circulación. La Junta tiene poder de voto compartido sobre todas las acciones pero sin poder de voto o disposición exclusivo; los derechos económicos permanecen con los beneficiarios asegurados.

La posición disminuyó en 1.161.259 acciones desde la enmienda del 28 de abril de 2025, principalmente por retiros de beneficiarios, el programa de compra y venta del Trust y la escisión rutinaria. Ningún director pagó por las acciones y no se anuncian nuevas adquisiciones, ventas o acciones estratégicas. La mecánica de votación, los derechos de retiro de los beneficiarios y otras disposiciones del trust permanecen sin cambios. Aparte de la reducción rutinaria de acciones, el informe no contiene transacciones materiales ni cambios en la intención de control corporativo.

MetLife, Inc. � Schedule 13D/A (수정� 번호 102)

이사회는 단일 보고자로� 2000� 변상조� 해체 과정에서 설립� MetLife Policyholder Trust가 보유� 보통주에 대� 공시� 업데이트합니�. 2025� 7� 31� 기준으로 신탁은 108,242,821�� 보유하고 있으�, 이는 발행 주식� 16.28%� 해당합니�. 이사회는 모든 주식� 대� 공동 의결�� 보유하지� 단독 의결권이� 처분권은 없습니다; 경제� 권리� 보험 계약� 수혜자에� 귀속됩니다.

� 지분은 2025� 4� 28� 수정� 이후 1,161,259� 감소했으�, 주로 수혜� 인출, 신탁� 매매 프로그램 � 정기 소멸� 따른 것입니다. 이사들은 주식� 대� 대가� 지불하지 않았으며, 새로� 취득, 매각 또는 전략� 조치� 발표되지 않았습니�. 의결 방식, 수혜� 인출 권리 � 기타 신탁 조항은 변경되지 않았습니�. 정기적인 주식 감소 외에� 중요� 거래� 기업 지배권 변� 의도� 없습니다.

MetLife, Inc. � Schedule 13D/A (Amendement n° 102)

Le Conseil d'administration, agissant en tant que seul déclarant, met à jour sa divulgation sur les actions ordinaires détenues dans le MetLife Policyholder Trust créé lors de la démétualisation de 2000. Au 31 juillet 2025, le Trust détient 108 242 821 actions, représentant 16,28 % du capital en circulation. Le Conseil détient un pouvoir de vote partagé sur toutes les actions mais aucun pouvoir de vote ou de disposition exclusif ; les droits économiques restent aux bénéficiaires assurés.

La position a diminué de 1 161 259 actions depuis l'amendement du 28 avril 2025, principalement en raison des retraits des bénéficiaires, du programme d'achat-vente du Trust et des déchéances routinières. Aucun administrateur n'a payé de contrepartie pour les actions et aucune nouvelle acquisition, vente ou action stratégique n'est annoncée. Les modalités de vote, les droits de retrait des bénéficiaires et les autres dispositions du trust restent inchangés. Hormis la réduction routinière des actions, le dépôt ne contient aucune transaction importante ni changement d'intention de contrôle de l'entreprise.

MetLife, Inc. � Schedule 13D/A (Nachtrag Nr. 102)

Der Vorstand, als alleiniger Meldender, aktualisiert seine Angaben zu den Stammaktien, die im MetLife Policyholder Trust gehalten werden, der während der Demutualisierung im Jahr 2000 gegründet wurde. Zum 31. Juli 2025 hält der Trust 108.242.821 Aktien, was 16,28 % des ausstehenden Aktienkapitals entspricht. Der Vorstand besitzt gemeinsames Stimmrecht über alle Aktien, jedoch kein alleiniges Stimm- oder Verfügungsrecht; die wirtschaftlichen Rechte verbleiben bei den versicherten Begünstigten.

Die Position verringerte sich seit der Änderung vom 28. April 2025 um 1.161.259 Aktien, hauptsächlich aufgrund von Auszahlungen an Begünstigte, dem Kauf- und Verkaufsprogramm des Trusts sowie routinemäßiger Verfall. Kein Direktor hat eine Gegenleistung für die Aktien gezahlt, und es werden keine neuen Erwerbe, Verkäufe oder strategischen Maßnahmen angekündigt. Die Abstimmungsmodalitäten, die Auszahlungsrechte der Begünstigten und andere Trust-Bestimmungen bleiben unverändert. Abgesehen von der routinemäßigen Aktienreduktion enthält die Meldung keine wesentlichen Transaktionen oder Änderungen der Absicht zur Unternehmenskontrolle.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
*Unless otherwise indicated, all information relating to beneficial ownership of Shares by the Reporting Persons is as of July 31, 2025.


SCHEDULE 13D


Board of Directors of MetLife, Inc., as an entity
Signature:*
Name/Title:Carlos M. Gutierrez
Date:08/07/2025
Signature:*
Name/Title:Carla A. Harris
Date:08/07/2025
Signature:*
Name/Title:Laura J. Hay
Date:08/07/2025
Signature:*
Name/Title:R. Glenn Hubbard
Date:08/07/2025
Signature:*
Name/Title:Jeh C. Johnson
Date:08/07/2025
Signature:*
Name/Title:William E. Kennard
Date:08/07/2025
Signature:*
Name/Title:Michel A. Khalaf
Date:08/07/2025
Signature:*
Name/Title:Diana L. McKenzie
Date:08/07/2025
Signature:*
Name/Title:Denise M. Morrison
Date:08/07/2025
Signature:*
Name/Title:Christian Mumenthaler
Date:08/07/2025
Signature:*
Name/Title:Mark A. Weinberger
Date:08/07/2025
Comments accompanying signature:
*By /s/ John A. Hall John A. Hall Attorney-in-fact

FAQ

How many MetLife (MET) shares does the Policyholder Trust currently hold?

The Trust holds 108,242,821 common shares as of 31-Jul-2025.

What percentage of MetLife’s outstanding stock does this stake represent?

It represents 16.28 % of the company’s outstanding common stock.

How has the Trust’s share count changed since the previous 13D/A filing?

The position declined by 1,161,259 shares since 28-Apr-2025, mainly due to beneficiary withdrawals and program sales.

Who holds voting power over the Trust shares?

The Board has shared voting power; beneficiaries hold economic rights but cannot direct votes except on specific consent matters.

Does the filing signal any new acquisitions or sales by MetLife’s directors?

No. The amendment is an informational update; it reports no new insider purchases or dispositions.
MetLife

NYSE:MET

MET Rankings

MET Latest News

MET Latest SEC Filings

MET Stock Data

50.99B
665.05M
0.25%
91.76%
1.2%
Insurance - Life
Life Insurance
United States
NEW YORK